替米沙坦对肥胖性高血压患者体脂、血脂及胰岛素抵抗的影响

摘要

目的 探讨替米沙坦对肥胖性高血压患者体脂、血脂、胰岛素抵抗的影响.方法 BMI≥125 kg/m<'2>的原发性高血压患者60例,随机分成观察组和对照组,并分别给予替米沙坦和硝苯地平缓释片干预,观察干预前后BP、BMI、腰臀比(W/H)、TC、LDL-C、TG、胰岛素抵抗指数(IRI)、高敏C反应蛋白(hsCRP)等指标变化.结果 与干预前比较,干预后12、24周两组BP均下降(P＜0.01),干预后24周观察组W/H、TG、IRI、hsCRP下降(P＜0.01或P＜0.05).观察组IRI、hsCRP的变化与SBP、DBP、BMI、W/H、TG等呈直线相关.结论 替米沙坦除良好的降压外,有一定的减轻腹型肥胖、控制TG和改善胰岛素抵抗的作用.%Objective To investigate the effects of telmisartan on serum lipids and insulin resistance in patients with obesity hypertension. Methods Sixty patients with hypertension and BMI ≥ 25 kg/m2 were randomly divided into treatment group and control group (n= 30) treated with telmisartan and nifedipine, respectively. The expression levels of BP, BMI,W/H, TG, TC, LDL-C, IRI and hsCRP were examined before and after treatment for 12 and 24 weeks. Results Compared with pre-treatment, the BP in both groups decreased significantly after treatment for 12 and 24 weeks (P ＜ 0. 01 ).Simultaneously, the expression levels of W/H, TG, IRI, hsCRP were decreased significantly after 24 weeks in the treatment group ( P ＜ 0. 01 or P ＜ 0. 05 ). Correlation analysis proved that the expression levels of IRI, hsCRP were linearly related with SBP, DBP, BMI, W/H and TG. Conclusion Telmisartan can reduce BP and decrease the levels of W/H,TG, IRI with a certain extent.